Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Susan G. Komen Breast Cancer Foundation
Daiichi Sankyo UK Ltd.
Triple Negative Breast Cancer Foundation
Information provided by (Responsible Party):
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT01307891
First received: March 1, 2011
Last updated: July 1, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2017
  Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)